Ground News

Don't Just Read the News, Understand It.

onclive.com image

News from onclive.com

Your destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today.

We’ve aggregated 989 of onclive.com’s headlines and news stories over the past 3 months.

onclive.com’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

onclive.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about onclive.com

Where is onclive.com located?onclive.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top onclive.com News

The OncFive: Top Oncology Articles for the Week of 5/11

The OncFive: Top Oncology Articles for the Week of 5/11

The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.See the Story

Cemiplimab Displays Survival Benefits Over Chemotherapy in First-Line Advanced PD-L1–High NSCLC With Brain Metastases

Cemiplimab Displays Survival Benefits Over Chemotherapy in First-Line Advanced PD-L1–High NSCLC With Brain Metastases

First-line cemiplimab extended median PFS and OS vs chemotherapy in patients with untreated advanced NSCLC with brain metastases.Read Article

Dr Vlachou on the Rationale for Evaluating Perioperative Enfortumab Vedotin Plus Pembrolizumab in Upper Tract Urothelial CancerCancer

Maryland · Maryland

Dr Vlachou on the Rationale for Evaluating Perioperative Enfortumab Vedotin Plus Pembrolizumab in Upper Tract Urothelial CancerCancer

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.Read Article

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer

T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.Breast Cancer Read Article

Dr Ali on the Efficacy of CDK4/6 Inhibition in ER+, HER2+ Breast Cancer

Azka Ali, MD, discusses how data from the PATINA trial inform the role of CDK4/6 inhibition in ER-positive, HER2-positive breast cancer.Breast Cancer · Maryland See the Story

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer

Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.Read Article

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.Read Article

Dr Garcia on the Safety of Earlier Use of Lu 177 Vipivotide Tetraxetan PSMA+ mCRPC

Jorge A. Garcia, MD, discusses the safety of Lu 177 vipivotide tetraxetan earlier in the treatment course for PSMA–positive mCRPC.Read Article

Dr Pimenta on Ongoing Therapeutic Challenges in Soft Tissue Sarcomas

Erica Maria Pimenta, MD, discusses ongoing therapeutic and translational challenges in the treatment of soft tissue sarcomas.Maryland · Maryland Read Article

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.Read Article

Decoding T-Cell Lymphomas: An Approach to Diagnosis & Treatment

Kerry Savage, MD, MSc, and Neha Mehta-Shah, MD, discuss approaches to diagnosing and treating T-cell lymphomas.Maryland · Maryland Read Article

Breaking News Topics Related to onclive.com